$1.03
-0.07 (-6.36%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ADCT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
19 interventional · 1 observational · 1 expanded access · 12 with posted results
Held by 8 tracked-famous managers (Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., +3 more) · FINRA short interest 6.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)NCT04970901Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab | B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | 154 | 2027-03-31 | in 224 d | 2026-07-17 |
| Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT04384484Progression-free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 440 | 2026-03-31actual | — | 2026-04-28 |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)NCT05660395Number of Participants with Moderate or Severe Hepatic Impairment Who Experience a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · Basic science | Phase 1 | Terminatedsponsor's stated reason: This decision to close the study was made following interactions with regulatory authorities and in consideration of the challenges associated with this patient population. No safety information contributed to this decision. | Drug: Loncastuximab Tesirine | Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | 5 | 2026-06-25actual | — | 2026-07-20 |
| A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid TumorsNCT05389462Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decided to halt further development of ADCT-601 | Drug: ADCT-601, Gemcitabine | Advanced Solid Tumors | 128 | 2025-04-17actual | — | 2025-05-22 |
| Long-term Registry of Patients Treated With Loncastuximab TesirineNCT05160064observationalProgression-free Survival (PFS) | — | Withdrawnsponsor's stated reason: Sponsor administrative decision | — | B-Cell Lymphomas | 0 | Dec 2024 | — | 2022-06-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid TumorsNCT04972981Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ADCT-901 | Advanced Solid Tumors | 30 | 2024-09-13actual | — | 2025-05-22 |
| A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)NCT04974996Number of Participants Who Experience Dose Limiting Toxicities (DLTs) in Part 1Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Decision to not proceed with study. | Drug: Loncastuximab tesirine, Prednisone, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine | Diffuse Large B-Cell Lymphoma | 0 | 2024-03-11 | — | 2022-03-29 |
| A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)NCT05144009results2025-01-30CR RateNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The benefit-risk profile does not support continuation of the LOTIS-9 trial. | Drug: Loncastuximab Tesirine, Rituximab | Diffuse Large B-cell Lymphoma | 41 | 2024-01-22actual | — | 2025-01-30 |
| Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin LymphomaNCT04052997results2024-03-28Overall Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Camidanlumab Tesirine | Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | 117 | 2023-01-19actual | — | 2024-03-28 |
| Study of ADCT-301 in Patients With Selected Advanced Solid TumorsNCT03621982results2024-06-13Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study. | Drug: ADCT-301 · Biological: Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer | 78 | 2022-12-14actual | — | 2024-06-13 |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular LymphomaNCT04699461results2023-10-23Complete Response Rate (CRR)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Administrative decision (not due to safety reason) | Drug: Loncastuximab Tesirine, Idelalisib | Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | 6 | 2022-11-25actual | — | 2023-10-23 |
| Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaNCT03684694results2024-02-06Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Administrative decision | Drug: Loncastuximab Tesirine, Ibrutinib | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | 136 | 2022-11-08actual | — | 2024-02-06 |
| Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaNCT03685344results2021-10-26Number of Participants With a Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: In a limited number of patients, no additional activity was evident for the combination vs. loncastuximab tesirine monotherapy. | Drug: Loncastuximab Tesirine and Durvalumab | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | 13 | 2020-10-27actual | — | 2021-10-26 |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT03589469results2021-07-29Overall Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Loncastuximab tesirine | Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 145 | 2020-05-24actual | — | 2023-08-29 |
| Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid TumorsNCT03700294Dose Limiting ToxicityOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Change in clinical plan and drug supply | Drug: ADCT-601 | Advanced Solid Tumors | 18 | 2019-12-11actual | — | 2020-05-01 |
| Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin LymphomaNCT02432235results2021-07-13Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Camidanlumab tesirine | Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 133 | 2019-10-24actual | — | 2021-07-13 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)NCT02669017results2020-04-13Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: ADCT-402 | Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma | 183 | 2019-02-21actual | — | 2021-05-19 |
| Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)NCT02588092results2020-02-26Number of Participants Who Experienced Dose-Limiting Toxicities (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Slow enrollment | Drug: ADCT-301 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | 35 | 2018-08-29actual | — | 2020-02-26 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)NCT02669264results2019-09-26Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The study was early terminated prior to part 2 because of slow accrual. | Drug: ADCT-402 | Acute Lymphoblastic Leukemia | 35 | 2018-07-03actual | — | 2021-05-24 |
| Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) ExpressionNCT03125200results2019-08-28Number of Participants Who Experienced Dose-Limiting ToxicitiesOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Safety | Drug: ADCT-502 | Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer | 21 | 2018-04-05actual | — | 2021-02-01 |
| Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNCT04705454expanded access | — | No longer available | Biological: Loncastuximab Tesirine | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | — | — | — | 2021-05-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19